Through decades of prohibition, legacy growers have been preserving their golden goose: genetics. At the moment regulations could put these genetics in the hands of those that played no role in this preservation, excluding especially our indigenous knowledge systems. Lee Hymers does an in-depth analysis of this travesty.
The original article was published on LinkedIn on 17 February 2026 and is republished here with full permission from Lee Hymers.
Designed Risk: How the Plant Was Reformatted
Legalisation and structural change
Legalisation carried a promise of repair.
It was framed as the end of arrests that fractured communities. It was presented as recognition for farmers who had carried prohibition risk for decades. It was described as access for patients without stigma. It was sold as inclusion.
Retail storefronts opened. High-end packaging replaced plastic bags. Tax revenue entered state budgets. Arrest statistics shifted in some jurisdictions. Cannabis moved out of informal space and into regulated visibility. In many places, that visibility was taken as proof of progress.
In parallel, cannabis was entering a different kind of control system.
As cannabis entered regulated markets, it was translated into measurable active ingredients. Laboratory certificates became the primary proof of legitimacy. Percentage replaced phenotype in public conversation. Milligrams entered legislation. The plant began to appear less as an organism and more as a quantified set of constituents.
Visibility widened at the counter while definition was narrowing upstream.
Cannabis as a biological system
Cannabis is a botanical organism.
More than 550 plant compounds have been identified within it. Around 144 are recognised cannabinoids. More than 100 phytocannabinoids have been identified in cannabis, many of which are characteristic of the plant’s chemistry. The rest include flavonoids such as anthocyanins, terpenes, fatty acids, cellulose, lignin, waxes and lipids. These compounds interact continuously. They modulate one another’s expression. They influence effect through relationship rather than isolation.
The plant functions as a biochemical ecosystem.
International drug control frameworks schedule cannabis as a controlled substance, and Δ9-THC is treated as its principal psychoactive reference point. Regulatory language follows that focus. Public discourse mirrors it. Over time, the plant has become legally and commercially synonymous with one molecule. THC.
Cannabis is being reduced until it behaves like a drug.
Then regulated like a drug.
Then blamed for acting like a drug.
Once a botanical system is defined through a treaty-named molecule, scheduling, quantification, licensing and audit naturally organise around that reference point. Administrative convenience becomes governance logic. The organism remains present in cultivation, yet disappears inside legal definition.
That reduction sets precedent early and determines what is measured, which then determines what is controlled.
THC as organising lever
In adult-use markets, THC percentage functions as a simple reference point. Consumers compare numbers and higher percentages attract attention. The metric reflects demand and influences how value is recognised.
In global medical markets, the same focus produces a different structural outcome. Products receive medical licensing while purchasing behaviour continues to follow potency. Combustion and inhalation remain common delivery methods within pharmaceutical-aligned environments, and therapeutic language develops alongside controlled-substance handling at a molecular level.
THC appears throughout international narcotics conventions, and governance structures align closely with that designation. Regulation therefore follows the molecule.Licensing systems, compliance frameworks and risk models organise around its measurement. Treaty alignment provides structural direction and stabilises institutional response. Medical framing and potency benchmarks develop together inside this environment.
Once THC becomes the primary reference point, the surrounding system orients around it.
Risk assessment follows concentration. Quality becomes interpreted through percentage. Legitimacy stabilises through measurable chemistry. Centrality produces control because what is measured becomes what is managed.
This structure separates the plant into measurable components and directs regulation along molecular pathways rather than botanical ones.
Integrated chemistry becomes administratively inconvenient, and pharmaceutical frameworks provide the dominant model for governance.
From that point forward, governance manages fragments of the plant rather than the plant itself.
The atomic gram
Cannabis flower expresses its chemistry within physical limits. The plant distributes its compounds within a fixed chemical mass. Composition shifts, yet total capacity always remains constant.
As THC concentration rises, proportional space for CBD, CBG, CBC, terpenes and other modulatory compounds contracts. Distribution changes inside a closed system. The atomic gram remains stable but the internal balance shifts.
That shift shapes how the plant behaves. Evidence suggests CBD may attenuate some THC-associated psychotic-like effects in certain contexts. Terpenes influence absorption and overall effect. Ratio determines experience. As THC levels climb, modulation capacity narrows and chemical diversity compresses.
Market behaviour reinforces this movement, with potency operating as a visible signal of value. Medical frameworks often interpret concentration as efficacy. Breeding programmes follow demand and laboratory reporting amplifies visibility.
Over time, balance yields to concentration as the dominant measure of quality. The system rewards chemical dominance while interpreting harm through the same conditions that produced it.
The plant retains its full chemical diversity, yet legitimacy is assessed through only a single dominant metric.
Risk framing and policy response
Public discussion increasingly links cannabis risk to concentration. Psychosis headlines circulate alongside potency statistics. Emergency department data on Cannabinoid Hyperemesis Syndrome enters policy debate through heavy-use narratives. Cyclical Vomiting Syndrome appears in regulatory briefings. Research findings move through concentration metrics.
Risk exists and responses vary. The endocannabinoid system is complex and individual physiology differs. The way harm is framed determines how policy develops.
Attention remains centred on THC exposure. Risk becomes associated primarily with one compound and public understanding narrowly follows that association.
The plant expresses broader regulatory chemistry. CBD influences endocannabinoid regulation. Chemical ratios shape behavioural response. Ensemble interactions affect outcome. These variables rarely anchor regulatory direction.
THC thresholds tighten while CBD remains tightly governed despite its non-psychoactive profile and recognised therapeutic value in certain epileptic disorders. Harm discourse sustains THC at the centre of policy development, and that centrality supports continued expansion of control.
Institutional framing shapes governance, and governance reinforces the frame.
Risk narratives justify expanding control. That control executes through calculation.
Regulation through calculation
Regulatory control increasingly operates through calculation.
Delta-9 THC once defined hemp legality. Compliance depended on measured concentration, and crops could satisfy regulatory limits while expressing significant levels of THCA. Cultivation practices developed around that boundary.
Political pressure surrounding delta-8 prompted clarification. Hemp compliance shifted toward total THC calculation through USDA rules and state plan implementation. THCA converts mathematically into potential delta-9 through formula.
Plant chemistry remains unchanged, yet legal interpretation transforms.
Under total THC rules, fields that previously satisfied delta-9 testing can exceed regulatory limits. “Hot crops” become structurally likely, particularly where environmental conditions push cannabinoid expression higher. Insurance exposure rises, compliance forecasting becomes essential and production margins compress. Many farmers exit before enforcement compels the decision.
Arithmetic redraws the boundary of legality without altering a single seed. Definition tightens through calculation and permissible cultivation contracts accordingly.
Control expands through mathematics.
Molecular fragmentation
Cannabis functions as an integrated chemical system. Full-spectrum extracts reflect that integration. THC, CBD, CBC, CBG and a host of other minor cannabinoids, acids and terpenes exist in relationship with one another; their interaction shaping overall effect. Many patients rely on that chemical coherence.
Regulatory measurement separates what the plant expresses together. Per-container THC limits apply regardless of ratio. Total THC thresholds extend to finished products. Cold or unactivated extracts fall within conversion formulas.
Compounds that function collectively have now acquired separate legal identities.
As regulation follows individual molecules, the plant loses coherence within regulatory language. Integrated products become administratively difficult to maintain. Reformulation pressure increases and standardisation gradually displaces diversity.
Fragmentation reshapes understanding as well as production. Cannabis becomes organised into regulatory categories — THC, CBD, THCA, isolates, full-spectrum, hemp, medical, recreational. Each category carries separate thresholds and definitions. Technical language expands and shared understanding recedes.
Classification begins to replace cultivation. Participation requires fluency in regulatory terminology and dependence on administrative interpretation increases.
A fragmented plant that has been separated into manageable units, becomes easier to standardise, measure and govern.
CBD within molecular governance
Fragmentation extends to compounds positioned as stabilising influences within the plant.
CBD produces no intoxicating effect and demonstrates therapeutic value in several clinical contexts, including treatment-resistant epilepsy. Pharmaceutical development, including Epidiolex, established clinical recognition but only within controlled frameworks.
Regulatory treatment remains strict. Daily dose limits apply and high-grade CBD flower distinct from industrial hemp receives sustained scrutiny. Restrictions intensified well before delta-8 debates reshaped public attention.
This treatment reveals the underlying governance preference. If CBD regulation were driven primarily by risk or intoxication potential, the compound would circulate more freely than THC. Its non-psychoactive profile and established therapeutic applications would position it outside heavy restriction.
The opposite occurs. CBD remains tightly governed because molecular control frameworks require it. Allowing widespread CBD circulation outside pharmaceutical channels would demonstrate that cannabis compounds can be managed through agricultural and commercial pathways rather than controlled-substance infrastructure. That precedent would undermine the institutional architecture built around THC.
Governance continues to prioritise molecular definition over botanical context.
Isolation expands legitimacy. Pharmaceutical CBD gains acceptance through standardisation and controlled formulation. Cultivated CBD remains constrained within agricultural channels that carry higher regulatory friction.
The molecule becomes acceptable when separated from the plant. Oversight expands as chemistry detaches from cultivation.
CBD demonstrates the governing preference clearly. Integrated plant systems fragment into controlled compounds, and molecular definition establishes the pathway to legitimacy.
Rescheduling and institutional enclosure
Rescheduling retains cannabis within the Controlled Substances Act framework and formalises its position inside pharmaceutical governance.
Licensed operators receive institutional recognition, and banking access, interstate commerce and capital participation align with documented compliance. Traceability systems extend oversight from origin through final distribution.
Licensing requirements themselves function as capital barriers. Application fees, bonding requirements, facility specifications, security protocols, testing mandates and ongoing compliance costs create entry thresholds that exclude small-scale producers and legacy operators. The operators who carried cultivation risk through prohibition decades; those who preserved genetics, developed growing knowledge, and built community infrastructure; cannot access the capital necessary for legal participation.
The structure filters for institutional actors. Multi-state operators, pharmaceutical companies, and venture-backed entities absorb licensing costs as operational overhead. Independent cultivators encounter those same costs as insurmountable barriers.
Within licensed channels, cannabis circulates as a controlled pharmaceutical substance. Outside those channels, production carries continued criminal exposure. The plant operates within separate legal environments defined by regulatory status.
Rescheduling strengthens the federal pharmaceutical framework surrounding cannabis and reinforces institutional control over production and distribution. Alternative structural directions exist, yet current policy consolidates authority within existing governance systems.
This structure stabilises enclosure, all the while maintaining a narrative of reform.
Participation under molecular control
Structural enclosure shapes who can participate and how participation occurs.
When a plant is defined primarily through a psychoactive molecule, it enters the legal architecture built to govern that molecule. Drug control frameworks require licensing, documentation and formal oversight, and these systems are designed around measurable compounds rather than agricultural diversity.
Total THC arithmetic introduces instability for small-scale cultivation. Home-grow operates within conversion formulas developed for licensed operators. Hemp farmers navigate numerical limits based on potential chemistry, and full-spectrum producers work within thresholds that compress integrated profiles into administratively manageable figures.
As molecular definition expands, legitimate space narrows.
Fragmentation influences more than production. It reshapes access, understanding and authority within the system. When laboratory interpretation determines legal recognition, participation shifts toward institutions equipped to manage that interpretation. Knowledge migrates from cultivation to certification, and authority follows the same path.
Small producers encounter structural barriers within molecular compliance frameworks. Consumers engage increasingly technical definitions that distance them from the plant itself. Cultural familiarity yields to regulatory literacy.
A plant once understood through practice becomes accessible only through permission. Participation becomes conditional.
Closing Synthesis
Issue #1 of Professional Misfit examined how genetic access determines market participation; how control at the seed level shapes every downstream outcome. This issue demonstrates how molecular definition performs the same function at a different layer.
Genetic origin and chemical composition both serve as control points. Regulators impose requirements at each layer. Together, they construct a system where participation requires institutional capacity rather than botanical knowledge or cultivation skill.
Legalisation expanded visibility.
Redefinition determined control.
The plant was never released from governance. It was redefined to fit within it.
And the rules of governance tend to favour those in position to define them.
.
Excellent and eloquent article! Analysing the big picture about the regulatory fixation with individual molecules, and how this ultimately allows powerful people from outside the culture (and sometimes with allies from inside the culture unfortunately) to enclose and profit from the plant. All at the expense of stewards who’ve carried the fire throughout the centuries, including the rain storm of prohibition, and also at the expense of people who’ve relied on fuller-spectrum, phytochemical symphonies of landraces and heirlooms.